Chronic Use of β-Blockers and the Risk of Parkinson’s Disease
Most patients with Parkinson’s disease exhibit intracellular accumulation of the α-synuclein protein encoded by the α-synuclein gene. It was recently shown that β2-adrenoreceptor agonists downregulate this gene, decreasing the apparent risk of Parkinson’s disease by up to 40%. In contrast, exposure to β-blocking drugs increases production of the α-synuclein protein.
The aim of this study was to examine whether chronic exposure to β-blockers is associated with an increased risk for Parkinson’s disease.
Patients and Methods
From the electronic charts of Maccabi Health Services, we identified all patients receiving their first β-blocker treatment between 1998 and 2004, and followed them up, for a diagnosis of Parkinson’s disease, between 2005 and 2016. We calculated the morbidity hazard of Parkinson’s disease diagnosis in users of β-blockers compared with non-users, as well as users of angiotensin-converting enzyme (ACE) inhibitors for hypertension, after adjusting for sex, age, weight, smoking status, cholesterol levels and use of statins, employing the Cox proportional hazard model. We also conducted a Kaplan–Meier survival analysis.
Overall, 145,098 patients received β-blockers, and 1,187,151 patients did not. The adjusted hazard ratio for Parkinson’s disease among β-blocker users was 1.51 (95% confidence interval 1.28–1.77; p < 0.0001). In contrast, the Parkinson’s disease morbidity hazard for patients receiving ACE inhibitors was no different than for the general population. The morbidity risk showed the effect of cumulative dose response with low threshold levels.
Chronic use of β-blockers confers a time- and dose-dependent increased risk for Parkinson’s disease. In view of the available alternatives for β-blockers, their chronic use should be carefully reconsidered.
The authors wish to thank Esma Herzl for coordinating the data retrieval.
GK and GN contributed to the conception and design of the study; GN, KR, VS, and GK contributed to the acquisition and analysis of the data; and GK and GN contributed to drafting the text and preparing the figures.
Compliance with Ethical Standards
No sources of funding were used to conduct this study.
Conflict of interest
Gideon Koren, Galia Norton, Kira Radinsky and Varda Shalev have no potential conflicts of interest to report.
Anonymized data will be shared upon reasonable request from any qualified investigator, pending approval from Maccabi Health Services and the Assuta Research Ethics Committee.
All procedures in this study were in accordance with the 1964 Helsinki declaration and its amendments, and the study was approved by the Assuta Ethics Committee.
As this study is based on anonymous data, the committee waived informed consent.
- 2.Wong SL, Gilmour H, Ramage-Morin PL. Parkinson’s disease: prevalence, diagnosis and impact. Health Rep. 2014;25(11):10–4.Google Scholar
- 3.de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S21–3.Google Scholar
- 5.Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.Google Scholar
- 10.Global RPh. Beta blockers: Comparative properties. 2004. http://www.globalrph.com/beta_blockers.htm. Accessed 22 Feb 2019.
- 11.Rodríguez-Violante M, Cervantes-Arriaga A, Fahn S, et al. Two-hundred years later: is Parkinson’s disease a single defined entity? Rev Investig Clin. 2017;69:308–9.Google Scholar
- 15.ABC News. More Americans taking prescription drugs. https://abcnews.go.com/health/wellness/prescription-drug-soars-us/story?id=11547284. Accessed 26 Feb 2019.
- 16.PRB. Population reference bureau. 2016. http://www.prb.org/Publications/Media-Guides/2016/aging-unitedstates-fact-sheet.aspx. Accessed 1 Dec 2018.
- 17.Parkinsons News Today. Parkinson’s disease statistics. 2018. https://parkinsonsnewstoday.com/parkinsons-disease-statistics. Accessed 1 Dec 2018.